Mignot A, Lefebvre M A, Couet W, Dourthe C, Marechaud R, Fourtillan J B
Therapie. 1989 Jul-Aug;44(4):253-6.
The kinetic of sulindac and its two metabolites (sulfide and sulfone) was investigated in twelve elderly patients, following multiple oral dose administration of 400 mg/d. Data were compared to those obtained previously in ten healthy volunteers who received the same dosage regimen. Following multiple dose administration, accumulation ratios indicate that sulindac do not accumulate either in elderly patients (R = 1.35; R = AUC0-24 J8/AUC0-24 J1) or in healthy young subjects (R = 1.38; R = U0-24 J1). No significant modification of sulindac and sulfide kinetic parameters was observed. The apparent bioavailability of the inactive metabolite, sulfone, was found to be doubled in elderly patients (p less than 0.05). We conclude that there is no need to modify the dosage regimen of Arthrocine (400 mg once a day) in elderly patients.
在12名老年患者中，在每日多次口服400毫克的剂量后，研究了舒林酸及其两种代谢产物（硫化物和砜）的动力学。将数据与先前在10名接受相同给药方案的健康志愿者中获得的数据进行比较。多次给药后，蓄积率表明舒林酸在老年患者（R = 1.35；R = AUC0 - 24 J8/AUC0 - 24 J1）或健康年轻受试者（R = 1.38；R = U0 - 24 J1）中均不蓄积。未观察到舒林酸和硫化物动力学参数的显著改变。发现无活性代谢产物砜在老年患者中的表观生物利用度增加了一倍（p小于0.05）。我们得出结论，老年患者无需调整Arthrocine（每日一次400毫克）的给药方案。
